Drugs
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Drugs
May 21, 2024, 00:04 |
Blog
Christos Tsagkaris: Health through the life course - Breaking down silos
Christos Tsagkaris, Greek Representative at EVID Action Youth Network at the WHO Regional Office for Europe, shared…
May 17, 2024, 12:54 |
Insight
Piotr Wysocki: Anti-HER2 treatment in patients with advanced biliary cancer
Piotr Wysocki recently posted on LinkedIn: "The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is…
Apr 28, 2024, 21:10 |
Drugs
Doug Rubinson: The best drug in GI cancers is 5-FU
Doug Rubinson, GI Medical Oncologist At Dana-Farber Cancer Centre, shared on X/Twitter: "In oncology, we…
Apr 19, 2024, 20:03 |
Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 19, 2024, 06:36 |
Societies
Lynn Schuchter: Urging Congress to help end drug shortages
Lynn Schuchter recently shared on X: "Scenes from ASCO Advocacy Summit where we’re urging Congress…
Apr 18, 2024, 13:55 |
Blog
Erman Akkus: How Genetic Testing Revolutionizes Care for Young Breast Cancer Survivors and Advances in Anaplastic Thyroid Carcinoma Treatment
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "1. Second primary breast…
Apr 17, 2024, 18:37 |
Blog
Piotr Wysocki: A new, broad-spectrum RAS-GTP inhibitor holds promise in pancreatic cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 14, 2024, 11:39 |
Drugs
Nieves Martinez Lago: FDA approvals Tumor-Agnostic drugs
Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X/Twitter: "FDA…
Apr 14, 2024, 03:52 |
Drugs
Piotr Wysocki: CLEAR trial – another study demonstrating that Immunotherapy and TKI combination should not be routinely recommended to favorable-risk RCC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 13, 2024, 08:14 |
Blog
David Fajgenbaum: Did you know behind every FDA approved drug lies numerous potential disease applications considered by drug companies?
David Fajgenbaum, Associate Professor of Medicine at University of Pennsylvania School of Medicine, shared on X:…
Apr 11, 2024, 12:38 |
Blog
Key drugs at AACR 2024 by LARVOL
LARVOL shared on X/Twitter: "Exploring the key drugs at AACR 2024? Dive into the abstracts, including…
Apr 8, 2024, 15:41 |
Drugs
Tom Powles: This seems an ambitious accelerated approval in UC
Tom Powles, Director of Barts Cancer Center, recently shared on X: "TDXD received FDA accelerated…
Mar 31, 2024, 08:18 |
Drugs
Jeffrey Martin: Bispecific antibodies - what are they and who's making them?
Jeffrey Martin, Founder of Oncoleader, recently shared on LinkedIn: "Bispecific antibodies: what are they and…
Mar 30, 2024, 21:20 |
Drugs
Vincent Rajkumar: 2 years later, over 2000 drugs - at low prices
Vincent Rajkumar, Editor in Chief of Blood Cancer Journal, shared a post by Eric Feigl-Ding,…
Mar 10, 2024, 20:55 |
Blog
Christos Tsagkaris: Highlights from the Congress for Children in Orthopaedics and Trauma Surgery in Münster, Germany
Christos Tsagkaris, Orthopaedic Surgery Resident at Children's Hospital Zurich, posted on LinkedIn: "Congress for Children…
Feb 28, 2024, 15:03 |
Blog
Cristina Jauset Gonzalez: Flagship Pioneering's newest stealth biotech start-up, FL102, is looking for its first two scientists!
Cristina Jauset Gonzalez, Associate at Flagship Pioneering, made the following post on LinkedIn: "Flagship Pioneering's…
Feb 18, 2024, 14:12 |
Blog
Don't miss the Cancer Medicines Forum workshop! - EORTC
Quoting EORTC - European Organisation for Research and Treatment of Cancer on LinkedIn "Don't miss…
Feb 14, 2024, 18:13 |
Drugs
Liposomal Irinotecan now FDA Oncology approved for 1L metastatic Pancreatic Cancer based off NAPOLI3 - Oncology Brothers
Oncology Brothers made the following post on X: "Liposomal Irinotecan now FDA Oncology approved for…
Feb 10, 2024, 15:18 |
Drugs
Erman Akkus: Localized pancreatic adenocancer treated with initial neoadjuvant FOLFIRINOX
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "Localized pancreatic adenocancer treated with…
Jan 5, 2024, 23:07 |
Blog
Aaron Goodman: I love this trial
Aaron Goodman shared a post on X/Twitter: “I love this trial. Less of a drug just…
Jan 2, 2024, 05:29 |
Drugs
Our end-of-year wrap-up tradition - Oncology Brothers
Quoting Oncology Brothers on X/Twitter: "Yet another busy year for FDA Oncology. ≥ 40 new…
Dec 23, 2023, 03:22 |
Blog
Talha Badar: ASH23 Highlights for me
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:…
Dec 7, 2023, 18:54 |
Blog
Paul Markovich: The American healthcare system spent more than $600 billion on prescription drugs in 2021 alone
Paul Markovich, President and CEO of Blue Shield of California, recently shared on LinkedIn: "The…
Dec 5, 2023, 18:58 |
Stories
David Fajgenbaum: My doctors gave me a 1 in a million chance to find a cure to my disease
David Fajgenbaum, Physician-Scientist at University of Pennsylvania and Co-Founder at Every Cure, made the following…
Nov 22, 2023, 10:48 |
Drugs
President Biden: We took on Big Pharma and won.
President of the United States Joe Biden shared on X (Twitter): "In 2021, drug companies…
Nov 4, 2023, 00:25 |
Insight
María Natalia Gandur Quiroga: After a successful ESMO 23, ADC continues to shine
María Natalia Gandur Quiroga shared a post on X/Twitter: “After a successful ESMO 23, ADC…
Oct 18, 2023, 18:00 |
Drugs
Vivek Subbiah: My perspectives of tumor agnostic drug development
Vivek Subbiah recently shared on LinkedIn: "So honored to present the “Future of Tissue-Agnostic Precision…
Oct 14, 2023, 17:49 |
Drugs
Chris Boshoff: the U.S. FDA approved our targeted combination therapy for the treatment of adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
Sep 7, 2023, 22:30 |
Blog
Chiquita Brooks-LaSure: For the 1st time Medicare can negotiate directly with drug companies & improve access to treatments for millions.
Chiquita Brooks-LaSure, American healthcare policy official who is the administrator of the Centers for Medicare…
Aug 29, 2023, 19:13 |
Insight
Rafael Fonseca: Some musings on myeloma therapy after coming back from ASCO and EHA 2023.
Rafael Fonseca, the Chief Innovation Officer at Mayo Clinic, Arizona, recently tweeted: "Some musings on…
Aug 22, 2023, 09:55 |
Drugs
Neeraj Agarwal: Breaking news: Glad to report the news from ph3 Contact-2 trial Cabozantinib + atezolizumab significantly improved outcomes in mCRPC prostate cancer.
Neeraj Agarwal stated on Twitter: "Breaking news: Glad to report the news from ph3 Contact-2 trial…
Aug 16, 2023, 19:43 |
Drugs
Arndt Vogel: FDA approves Melphalan as a liver-directed treatment for uveal melanoma.
Arndt Vogel, Head of the GI-Cancer Center and of the Center for Personalized Medicine at…
Aug 14, 2023, 19:57 |
Drugs
Shikha Jain: We Need Chemo Drugs!
Quoting from a recent Twitter post by Shikha Jain, President, CEO Founder of Women in…
Aug 14, 2023, 18:42 |
Blog
Elizabeth F. Franklin: In order for Indian Health Service (IHS) institutions to be able to cover specialty drugs, the CMS payment rate must be augmented.
As stated by Elizabeth F. Franklin, Head of US Public Affairs and Patient Advocacy, on…
Aug 14, 2023, 17:26 |
Insight
Raffaele Colombo: WHO INN proposed list 129 is out.
In a Twitter post by Raffaele Colombo, Principal Scientist at Zymeworks Inc, it says: ''WHO…
Aug 13, 2023, 18:49 |
Insight
Hinco J. Gierman: It underscores the importance of rapid testing and getting patients on the right treatment.
As stated by Hinco J. Gierman, Vice President of Precision Oncology, on LinkedIn: "We published…
Aug 13, 2023, 09:17 |
Drugs
TALVEY (Talquetamab) is now FDA approved - Mark Wildgust
In a tweet by Mark Wildgust, Vice President of Oncology Global Medical Affairs at Janssen,…
Aug 11, 2023, 19:30 |
Drugs
Vivek Subbiah: Pralsetinib has received FULL FDA approval
Exciting News for RET+ patients! Pralsetinib has received FULL FDA approval! From treating the 1st…
Aug 11, 2023, 18:48 |
Insight
Amer Zeidan: On behalf of an international panel, we issued a call-for-action to harmonize/unify WHO22 and ICC22 classifications for AML
On behalf of an international panel, we issued a call-for-action to harmonize/unify WHO22 & ICC22…
Aug 11, 2023, 17:13 |
Career
Jessica Clerc: I am thrilled to share that I have taken on a new role as Partnership Manager at the Union for International Cancer Control (UICC)
Exciting News! I am thrilled to share that I have taken on a new role…
Aug 9, 2023, 21:00 |
Drugs
Atezolizumab/bevacizumab for the management of HCC in 1st setting - Arndt Vogel
🔥 off the press: Atezolizumab/bevacizumab for the management of HCC in 1st setting: systematic literature…
Aug 7, 2023, 19:44 |
Drugs
This is a preventable tragedy- that we must avoid repeating - Manni Mohyuddin
Daratumumab has been known to be effective in relapsed myeloma for a long time. Yet…
Aug 4, 2023, 17:46 |
Blog
It becomes our obligation to address these inequities in cancer care and prevention - Richard Marlink
For five of the big cancer killers in sub-Saharan African, we reviewed how improved access…
Aug 3, 2023, 11:56 |
Blog
Top 10 reasons why ABIM MOC should be abolished - Vincent Rajkumar
Top 10 reasons why ABIM MOC should be abolished. 1. It has turned an MD…
Aug 1, 2023, 20:40 |
Drugs
Timely and important ASCO, Cancer.net blog written for patients, caregivers, and laypersons - Ishwaria Subbiah
Timely and important American Society of Clinical Oncology Cancer.net blog written for patients, caregivers, and…
Aug 1, 2023, 19:06 |
Blog
ASCO Breakthrough 2023 abstracts were just released - Tingting Zhang
ASCOBT23 abstracts were just released. Looking forward to discussing with the authors on how adverse…
Jul 31, 2023, 17:24 |
Drugs
Delighted to share our latest paper on "Tumor-agnostic drug development in dMMR/MSI-H solid tumors" just published in Trends in Cancer - Vivek Subbiah
Hot off the press! Weekend Reading. :arrow: Delighted to share our latest paper on "Tumor-agnostic…
Jul 24, 2023, 18:23 |
Drugs
These drugs are $$$! i.e. avapritinib = $44,000/bottle - Michael Lam
Patients on oral chemo after dose reduction: "I still have these pills at home, but…
Jul 23, 2023, 17:26 |
Drugs
Myeloma drugs - Dosing and schedule by Vincent Rajkumar on Twitter
Myeloma drugs — Dosing and schedule What I do in practice Dex: 40 mg…
Jul 23, 2023, 07:18 |
Societies
Hope Common Sense Oncology will infuse the spirit of critical appraisal in the hem/onc community, patients, and pt. advocates! - Raj Chakraborty
Excited to see the launch of Common Sense Oncology! Identifying drugs and outcomes that 𝐝𝐨…
Jul 15, 2023, 17:43 |
Drugs
Awesome talk by Dr. Rana McKay on the future perspectives of new drugs and compounds in RCC - Fabio Schutz
Awesome talk by Dr. Rana McKay on the future perspectives of new drugs and compounds…
Jul 8, 2023, 11:43 |
Stories
If you want decrease costs in myeloma - Aaron Goodman
If you want decrease costs in myeloma then 1. Don’t treat smoldering MM 2. Don’t…
Jul 7, 2023, 06:22 |
Blog
I recently wrote an op-ed with Bobby Green about the importance of better care coordination and patient navigation to achieve the goals of Cancer Moonshot for Fortune
In a post by Bradford Diephuis on Linkedin, it says, "I recently wrote an op-ed…
Jul 6, 2023, 05:11 |
Insight
Even weak evidence 3 drugs better than 2 - Vinay Prasad
New paper this week walks through the RCT landscape in myeloma and shows poor post-protocol…
Jul 5, 2023, 04:13 |
Drugs
European Commission Grants Conditional Marketing Authorization for Futibatinib for the Treatment of Adults With Cholangiocarcinoma
In a post by Arndt Vogel on Twitter, it says, "European Commission Grants Conditional Marketing…
Jun 30, 2023, 19:08 |
Drugs
Perioperative Nivolumab and Chemotherapy in stage III Non-Small-Cell Lung Cancer
In a post by Rami Manochakian on Twitter, it says, "Just published NEJM Results of…
Jun 30, 2023, 17:08 |
Blog
More important than prescribing the right pill is - Aaron Goodman
More important than prescribing the right pill is building trust with your patients and their…
Jun 28, 2023, 17:21 |
Blog
TNBC is a scourge on this earth - Rebecca Shatsky
TNBC is a scourge on this earth. I am so angry that this disease exists…
Jun 26, 2023, 19:25 |
Positive
We encourage our European colleagues to build a strong clinical trials infrastructure so that we can have more patients offered clinical trials and we can get to answers sooner
Jun 21, 2023, 18:41 |
Drugs
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC
In a post by Arun Azad on Twitter, it says, "So pleased (& a little…
All:
60
Posts:
1 - 100
Tedros Adhanom Ghebreyesus received University of Nicosia’s Honorary Doctorate
Lisa A. Lacasse: A major milestone towards Congress passing the bipartisan MCED Act
July is Sarcoma Awareness Month
25 Posts You Should Not Miss From ESMOGI24!
Monica Bertagnolli: Molecular Portrait of Key Driver of pancreatic cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube